IFNG and neoplasm: Ipilimumab may also rescue tumor-impaired IFN-γ pathways in CD4+ T cells [47], since a number of genes associated with IFN-γ signals such as STAT1, ISG15, GBp1, and EIF2AK2 were up-regulated by ipilimumab (data not shown).